PIM
RNAM

Platinum Investment Management’s Avidity Biosciences RNAM Stock Holding History

Platinum Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-94,496
Closed -$2.33M – 152
2021
Q3 		$2.33M Buy
94,496
+79,496
+530% +$1.73M 0.07% 95
2021
Q2 		$371K Hold
15,000
– – 0.01% 120
2021
Q1 		$327K Hold
15,000
– – 0.01% 118
2020
Q4 		$383K Hold
15,000
– – 0.01% 119
2020
Q3 		$422K Hold
15,000
– – 0.01% 117
2020
Q2 		$424K Buy
+15,000
New +$432K 0.01% 116

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Platinum Investment Management's RNAM Position: Q4 2021 in Review

Platinum Investment Management sold out of Avidity Biosciences (RNAM) in Q4 2021, closing a stake of 94,496 shares — an estimated $2.33M sold.

Platinum Investment Management first reported a position in RNAM in Q2 2020 and held it in 6 quarters. The position peaked at $2.33M in Q3 2021. 107 funds tracked by Wall St. Rank hold RNAM as of Q4 2021.

  • Platinum Investment Management reported no remaining Avidity Biosciences position as of Q4 2021 after selling out during the quarter.
  • Platinum Investment Management sold 94,496 Avidity Biosciences shares in Q4 2021, an estimated $2.33M.
  • Platinum Investment Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 6 quarters.
  • Platinum Investment Management's Avidity Biosciences position peaked at $2.33M in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2021.

Based on Platinum Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.